- Conditions
- Amblyopia, Ocular Motility Disorders
- Interventions
- iCare, Amblyopia standard of Care, CI standard of Care
- Device · Behavioral
- Lead sponsor
- Barron Associates, Inc.
- Industry
- Eligibility
- 4 Years to 18 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 409–432
of 729
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Leber's Hereditary Optic Neuropathy
- Interventions
- EPI-743
- Drug
- Lead sponsor
- Edison Pharmaceuticals Inc
- Industry
- Eligibility
- 8 Years to 65 Years
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Spasticity
- Interventions
- Rhizotomy for children with spasticity
- Procedure
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2017
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Vision Disorders, Sensation Disorders, Neurologic Manifestations, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Retinal Disease
- Interventions
- QR-110
- Drug
- Lead sponsor
- Laboratoires Thea
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 2
- States / cities
- Iowa City, Iowa • Philadelphia, Pennsylvania
- Conditions
- Metastatic Melanoma
- Interventions
- sunitinib malate, temozolomide
- Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2018
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder, Recurrent Idiopathic Longitudinally Extensive Transverse Myelitis
- Interventions
- Plasma exchange (PLEX)
- Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Rochester, Minnesota
- Conditions
- Cataract, Ophthalmoplegia, Ophthalmologic Complication
- Interventions
- MORCHER® EYEJET® CTR Types 14, 14A, and 14C, Toric IOL Only
- Device
- Lead sponsor
- Rachel Lieberman
- Federal
- Eligibility
- 30 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Nellis Air Force Base, Nevada
- Conditions
- Amblyopia
- Interventions
- Video Game Vision Training, Perceptual Learning, Occlusion Therapy
- Behavioral
- Lead sponsor
- Nova Southeastern University
- Other
- Eligibility
- Not listed
- Enrollment
- 180 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- Fort Lauderdale, Florida
- Conditions
- Optic Nerve Disorders
- Interventions
- Not listed
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Extraocular Retinoblastoma, Intraocular Retinoblastoma, Recurrent Retinoblastoma
- Interventions
- Laboratory Biomarker Analysis, Questionnaire Administration
- Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Not listed
- Enrollment
- 234 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2008
- U.S. locations
- 49
- States / cities
- Los Angeles, California • Madera, California • San Francisco, California + 38 more
- Conditions
- Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Anaplastic Oligoastrocytoma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Brain Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Glioblastoma, Recurrent Childhood Visual Pathway and Hypothalamic Glioma
- Interventions
- cilengitide, laboratory biomarker analysis, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 19
- States / cities
- Oakland, California • San Francisco, California • Washington D.C., District of Columbia + 16 more
- Conditions
- Neuromyelitis Optica Spectrum Disorder, NMOSD, AQP4+ NMOSD
- Interventions
- Not listed
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 6
- States / cities
- Washington D.C., District of Columbia • Boston, Massachusetts • Chapel Hill, North Carolina + 3 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Brolucizumab, Aflibercept
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 535 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 60
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Huntington Beach, California + 51 more
- Conditions
- Optic Neuritis
- Interventions
- Atacicept, Placebo matched to atacicept
- Drug
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Aurora, Colorado • Fairfield, Connecticut + 5 more
- Conditions
- Progressive Supranuclear Palsy
- Interventions
- Single dose C2N-8E12, Single dose placebo
- Drug
- Lead sponsor
- C2N Diagnostics
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 9 more
- Conditions
- Retinoblastoma
- Interventions
- Intra-arterial Chemotherapy
- Procedure
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 1 Month and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Normal Tension Glaucoma
- Interventions
- Not listed
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Ultomiris-exposed Pregnant/ Postpartum, Pregnancy, Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS), Generalized Myasthenia Gravis (gMG), Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Interventions
- Ultomiris
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- Female only
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2034
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- NMO Spectrum Disorder, Spasticity, Muscle
- Interventions
- Nabiximols, Placebo
- Drug
- Lead sponsor
- Michael, Levy M.D.,Ph.D.
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Acute Demylelinating Optic Neuritis
- Interventions
- Fingolimod 0.5mg/daily, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- St. Petersburg, Florida
- Conditions
- Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
- Interventions
- Eculizumab
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 15
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Miami, Florida + 11 more
- Conditions
- Exudative Retinal Detachment and Uveal Melanoma
- Interventions
- Dexamethasone intravitreal implant
- Drug
- Lead sponsor
- Ivana K. Kim
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Ischemic Optic Neuropathy/Optic Nerve Stroke
- Interventions
- NT-501 CNTF Implant
- Drug
- Lead sponsor
- Jeffrey L Goldberg
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Childhood Hepatoblastoma, Childhood Synovial Sarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Adrenocortical Carcinoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Liver Cancer, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive, Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Retinoblastoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors
- Interventions
- cixutumumab, laboratory biomarker analysis
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 7 Months to 30 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 93
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 78 more